Venous thromboembolism (VTE) is a serious complication that can occur during and after
postoperative treatment, including in treatment after orthopedic surgery. The current …

Introduction: Venous thromboembolism is highly associated with orthopedic surgery, so
thromboprophylaxis is an important consideration for orthopedic surgeons. The new oral …

Background: Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients
undergoing major orthopedic surgery (MOS). However, rivaroxaban has never been directly …

Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for
the prevention and treatment of venous thromboembolism (VTE). This analysis of pooled …

Background: The risk of venous thromboembolism is high in patients undergoing fracture-
related major orthopedic surgery, but data on pharmacological thromboprophylaxis are …

Patients undergoing non-major orthopedic surgery often face an increased risk of venous
thromboembolism due to the necessity of immobilization postoperatively. Current guidelines …

Background Nonmajor orthopedic surgery of the lower limbs that results in transient reduced
mobility places patients at risk for venous thromboembolism. Rivaroxaban may be …

Four multinational, randomized, double-blind, double-dummy phase III studies (RECORD1,
2, 3 and 4) investigated the oral, direct Factor Xa inhibitor rivaroxaban for the prevention of …

Objective: To review the pharmacology, pharmacokinetics, and clinical efficacy/safety protile
of rivaroxaban to inform health-care professionals of this new agent for the prevention of …

The RECORD program comprised four pivotal phase III trials comparing the oral direct
Factor Xa inhibitor, rivaroxaban, with subcutaneous enoxaparin for the prevention of venous …